Header Logo

Connection

MANJUSHA GAGLANI to Vaccination

Back to Details
This is a "connection" page, showing publications MANJUSHA GAGLANI has written about Vaccination.
MANJUSHA GAGLANI
Connection Strength
5.526
Vaccination
  1. Effects of Repeated Annual Inactivated Influenza Vaccination among Healthcare Personnel on Serum Hemagglutinin Inhibition Antibody Response to A/Perth/16/2009 (H3N2)-like virus during 2010-11. Vaccine. 2016 Feb 10; 34(7):981-8.
    View in: PubMed
    Score: 0.333
  2. Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States. J Infect Dis. 2016 May 15; 213(10):1546-56.
    View in: PubMed
    Score: 0.331
  3. Editorial commentary: school-located influenza vaccination: why worth the effort? Clin Infect Dis. 2014 Aug 01; 59(3):333-5.
    View in: PubMed
    Score: 0.295
  4. Potential influence of seasonal influenza vaccination requirement versus traditional vaccine promotion strategies on unvaccinated healthcare personnel. Vaccine. 2013 Aug 20; 31(37):3915-21.
    View in: PubMed
    Score: 0.278
  5. Patient- and Community-Level Characteristics Associated With Respiratory Syncytial Virus Vaccination. JAMA Netw Open. 2025 04 01; 8(4):e252841.
    View in: PubMed
    Score: 0.157
  6. COVID-19 Vaccination and Odds of Post-COVID-19 Condition Symptoms in Children Aged 5 to 17 Years. JAMA Netw Open. 2025 02 03; 8(2):e2459672.
    View in: PubMed
    Score: 0.155
  7. Protection From COVID-19 Vaccination and Prior SARS-CoV-2 Infection Among Children Aged 6 Months-4 Years, United States, September 2022-April 2023. J Pediatric Infect Dis Soc. 2025 Jan 20; 14(1).
    View in: PubMed
    Score: 0.155
  8. Reduced Effectiveness of Repeat Influenza Vaccination: Distinguishing Among Within-Season Waning, Recent Clinical Infection, and Subclinical Infection. J Infect Dis. 2024 Dec 16; 230(6):1309-1318.
    View in: PubMed
    Score: 0.154
  9. Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized, Open-Label Trial. Clin Infect Dis. 2023 02 08; 76(3):e1168-e1176.
    View in: PubMed
    Score: 0.135
  10. Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers. JAMA. 2022 10 18; 328(15):1523-1533.
    View in: PubMed
    Score: 0.132
  11. Vaccine Effectiveness Against Acute Respiratory Illness Hospitalizations for Influenza-Associated Pneumonia During the 2015-2016 to 2017-2018 Seasons: US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). Clin Infect Dis. 2022 04 28; 74(8):1329-1337.
    View in: PubMed
    Score: 0.128
  12. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 27; 70(34):1156-1162.
    View in: PubMed
    Score: 0.122
  13. Vaccine Effectiveness Against Influenza-Associated Hospitalizations Among Adults, 2018-2019, US Hospitalized Adult Influenza Vaccine Effectiveness Network. J Infect Dis. 2021 07 02; 224(1):151-163.
    View in: PubMed
    Score: 0.121
  14. Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011-2012 to 2016-2017. Clin Infect Dis. 2021 04 08; 72(7):1147-1157.
    View in: PubMed
    Score: 0.119
  15. Effects of Influenza Vaccination in the United States During the 2017-2018 Influenza Season. Clin Infect Dis. 2019 11 13; 69(11):1845-1853.
    View in: PubMed
    Score: 0.108
  16. Influenza Vaccine Effectiveness and Statin Use Among Adults in the United States, 2011-2017. Clin Infect Dis. 2019 05 02; 68(10):1616-1622.
    View in: PubMed
    Score: 0.104
  17. Association of Prior Vaccination With Influenza Vaccine Effectiveness in Children Receiving Live Attenuated or Inactivated Vaccine. JAMA Netw Open. 2018 10 05; 1(6):e183742.
    View in: PubMed
    Score: 0.100
  18. Influenza Vaccine Effectiveness for Fully and Partially Vaccinated Children 6 Months to 8 Years Old During 2011-2012 and 2012-2013: The Importance of Two Priming Doses. Pediatr Infect Dis J. 2016 Mar; 35(3):299-308.
    View in: PubMed
    Score: 0.084
  19. Barriers and facilitators to influenza vaccination and vaccine coverage in a cohort of health care personnel. Am J Infect Control. 2014 Apr; 42(4):371-5.
    View in: PubMed
    Score: 0.073
  20. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2014 Feb; 58(3):319-27.
    View in: PubMed
    Score: 0.071
  21. The expected emotional benefits of influenza vaccination strongly affect pre-season intentions and subsequent vaccination among healthcare personnel. Vaccine. 2012 May 21; 30(24):3557-65.
    View in: PubMed
    Score: 0.064
  22. Influenza Vaccine Effectiveness Against Medically Attended Outpatients Illness, United States, 2023-2024 Season. Clin Infect Dis. 2025 Nov 06; 81(4):e184-e191.
    View in: PubMed
    Score: 0.041
  23. RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons. JAMA. 2025 Oct 28; 334(16):1442-1451.
    View in: PubMed
    Score: 0.041
  24. Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations, United States, 1 September 2023 to 31 May 2024. J Infect Dis. 2025 Oct 15; 232(4):e626-e636.
    View in: PubMed
    Score: 0.041
  25. Recombinant quadrivalent influenza vaccine (RIV) induces robust cell-mediated and HA-specific B cell humoral immune responses among healthcare personnel. Vaccine. 2025 Aug 13; 61:127361.
    View in: PubMed
    Score: 0.040
  26. Intrinsic immunogenicity is a major determinant of type-specific responses in SARS-CoV-2 infections. Nat Immunol. 2025 Jun; 26(6):829-836.
    View in: PubMed
    Score: 0.040
  27. Influenza Vaccine Effectiveness Against Illness and Asymptomatic Infection in 2022-2023: A Prospective Cohort Study. Clin Infect Dis. 2025 Apr 30; 80(4):893-900.
    View in: PubMed
    Score: 0.039
  28. Association of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination and Reductions in Post COVID Conditions Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection in a US Prospective Cohort of Essential Workers. J Infect Dis. 2025 Mar 17; 231(3):665-676.
    View in: PubMed
    Score: 0.039
  29. Effectiveness of the Original Monovalent Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination Series Against Hospitalization for COVID-19-Associated Venous Thromboembolism. J Infect Dis. 2025 Feb 20; 231(2):378-385.
    View in: PubMed
    Score: 0.039
  30. COVID-19 and influenza vaccine Hesitancy among adults hospitalized in the United States, 2019-2022. Vaccine. 2025 02 27; 48:126806.
    View in: PubMed
    Score: 0.039
  31. Risk reduction in SARS-CoV-2 infection and reinfection conferred by humoral antibody levels among essential workers during Omicron predominance. PLoS One. 2024; 19(12):e0306953.
    View in: PubMed
    Score: 0.039
  32. Molecular features of the serological IgG repertoire elicited by egg-based, cell-based, or recombinant haemagglutinin-based seasonal influenza vaccines: a comparative, prospective, observational cohort study. Lancet Microbe. 2025 Feb; 6(2):100935.
    View in: PubMed
    Score: 0.038
  33. Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses - IVY Network, September 1, 2022-March 30, 2023. Vaccine. 2025 01 01; 43(Pt 2):126492.
    View in: PubMed
    Score: 0.038
  34. Effectiveness of Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Hospitalization and Severe In-Hospital Outcomes Among Adults in the United States, September 2022-August 2023. Influenza Other Respir Viruses. 2024 11; 18(11):e70027.
    View in: PubMed
    Score: 0.038
  35. Elevated body mass index is not significantly associated with reduced influenza vaccine effectiveness. Sci Rep. 2024 09 13; 14(1):21466.
    View in: PubMed
    Score: 0.038
  36. Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023. J Infect Dis. 2024 Jul 25; 230(1):141-151.
    View in: PubMed
    Score: 0.037
  37. Hybrid Immunity and SARS-CoV-2 Antibodies: Results of the HEROES-RECOVER Prospective Cohort Study. Clin Infect Dis. 2024 07 19; 79(1):96-107.
    View in: PubMed
    Score: 0.037
  38. Effectiveness of the influenza vaccine for preventing laboratory-confirmed influenza infections in outpatient immunocompromised adults, 2017-2018. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2354013.
    View in: PubMed
    Score: 0.037
  39. Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022-April 2023. Influenza Other Respir Viruses. 2024 06; 18(6):e13342.
    View in: PubMed
    Score: 0.037
  40. Vaccine Effectiveness Against Influenza A-Associated Hospitalization, Organ Failure, and Death: United States, 2022-2023. Clin Infect Dis. 2024 04 10; 78(4):1056-1064.
    View in: PubMed
    Score: 0.037
  41. Vaccine Effectiveness Against Pediatric Influenza-A-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2022-2023 Season: VISION Network. Clin Infect Dis. 2024 03 20; 78(3):746-755.
    View in: PubMed
    Score: 0.036
  42. Risk of COVID-19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders. Influenza Other Respir Viruses. 2024 03; 18(3):e13269.
    View in: PubMed
    Score: 0.036
  43. Longitudinal parental perception of COVID-19 vaccines for children in a multi-site, cohort study. Vaccine. 2024 03 07; 42(7):1512-1520.
    View in: PubMed
    Score: 0.036
  44. Redirecting antibody responses from egg-adapted epitopes following repeat vaccination with recombinant or cell culture-based versus egg-based influenza vaccines. Nat Commun. 2024 01 04; 15(1):254.
    View in: PubMed
    Score: 0.036
  45. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med. 2004 Jan; 158(1):65-73.
    View in: PubMed
    Score: 0.036
  46. Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design. Vaccine. 2023 12 12; 41(51):7581-7586.
    View in: PubMed
    Score: 0.036
  47. Vaccine Effectiveness Against Influenza-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2021-2022 Season, VISION Network. J Infect Dis. 2023 07 14; 228(2):185-195.
    View in: PubMed
    Score: 0.035
  48. Protection From COVID-19 mRNA Vaccination and Prior SARS-CoV-2 Infection Against COVID-19-Associated Encounters in Adults During Delta and Omicron Predominance. J Infect Dis. 2023 06 15; 227(12):1348-1363.
    View in: PubMed
    Score: 0.035
  49. Comparison of mRNA vaccine effectiveness against COVID-19-associated hospitalization by vaccination source: Immunization information systems, electronic medical records, and self-report-IVY Network, February 1-August 31, 2022. Vaccine. 2023 06 29; 41(29):4249-4256.
    View in: PubMed
    Score: 0.034
  50. Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents. Pediatrics. 2023 05 01; 151(5).
    View in: PubMed
    Score: 0.034
  51. Influenza Vaccine Effectiveness Against Influenza A(H3N2)-Related Illness in the United States During the 2021-2022 Influenza Season. Clin Infect Dis. 2023 04 17; 76(8):1358-1363.
    View in: PubMed
    Score: 0.034
  52. Influenza Vaccine Effectiveness Among Children: 2011-2020. Pediatrics. 2023 04 01; 151(4).
    View in: PubMed
    Score: 0.034
  53. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. JAMA Netw Open. 2023 03 01; 6(3):e232598.
    View in: PubMed
    Score: 0.034
  54. Burden of medically attended influenza infection and cases averted by vaccination - United States, 2016/17 through 2018/19 influenza seasons. Vaccine. 2022 12 12; 40(52):7703-7708.
    View in: PubMed
    Score: 0.033
  55. Multiplex Detection of Antibody Landscapes to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/Influenza/Common Human Coronaviruses Following Vaccination or Infection With SARS-CoV-2 and Influenza. Clin Infect Dis. 2022 10 03; 75(Suppl 2):S271-S284.
    View in: PubMed
    Score: 0.033
  56. Parental Intentions and Perceptions Toward COVID-19 Vaccination Among Children Aged 4 Months to 4 Years - PROTECT Cohort, Four States, July 2021-May 2022. MMWR Morb Mortal Wkly Rep. 2022 09 02; 71(35):1109-1114.
    View in: PubMed
    Score: 0.033
  57. Ascertainment of vaccination status by self-report versus source documentation: Impact on measuring COVID-19 vaccine effectiveness. Influenza Other Respir Viruses. 2022 11; 16(6):1101-1111.
    View in: PubMed
    Score: 0.032
  58. COVID-19 Vaccination Perspectives and Illnesses Among Law Enforcement Officers, Firefighters, and Other First Responders in the US, January to September 2021. JAMA Netw Open. 2022 07 01; 5(7):e2222640.
    View in: PubMed
    Score: 0.032
  59. Vaccine-associated attenuation of subjective severity among outpatients with influenza. Vaccine. 2022 07 30; 40(32):4322-4327.
    View in: PubMed
    Score: 0.032
  60. Consistency of self-reported and documented historical influenza vaccination status of US healthcare workers. Influenza Other Respir Viruses. 2022 09; 16(5):881-890.
    View in: PubMed
    Score: 0.032
  61. Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers. N Engl J Med. 2022 05 12; 386(19):1855-1857.
    View in: PubMed
    Score: 0.032
  62. Rationale and approach to target children with asthma for annual influenza immunization. Semin Pediatr Infect Dis. 2002 Apr; 13(2):97-103.
    View in: PubMed
    Score: 0.032
  63. Interim Estimates of 2021-22 Seasonal Influenza Vaccine Effectiveness - United States, February 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 11; 71(10):365-370.
    View in: PubMed
    Score: 0.032
  64. Role of Age in the Spread of Influenza, 2011-2019: Data From the US Influenza Vaccine Effectiveness Network. Am J Epidemiol. 2022 02 19; 191(3):465-471.
    View in: PubMed
    Score: 0.032
  65. Vaccine effectiveness against COVID-19 among symptomatic persons aged =12?years with reported contact with COVID-19 cases, February-September 2021. Influenza Other Respir Viruses. 2022 07; 16(4):673-679.
    View in: PubMed
    Score: 0.032
  66. Incidence of SARS-CoV-2 infection among COVID-19 vaccinated and unvaccinated healthcare personnel, first responders, and other essential and frontline workers: Eight US locations, January-September 2021. Influenza Other Respir Viruses. 2022 05; 16(3):585-593.
    View in: PubMed
    Score: 0.031
  67. Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-Nine States, January-September 2021. Am J Transplant. 2022 01; 22(1):306-314.
    View in: PubMed
    Score: 0.031
  68. COVID-19 vaccine perceptions and uptake in a national prospective cohort of essential workers. Vaccine. 2022 01 24; 40(3):494-502.
    View in: PubMed
    Score: 0.031
  69. Effect of Antigenic Drift on Influenza Vaccine Effectiveness in the United States-2019-2020. Clin Infect Dis. 2021 12 06; 73(11):e4244-e4250.
    View in: PubMed
    Score: 0.031
  70. Effectiveness of Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Hospitalizations in Immunocompromised Adults. Clin Infect Dis. 2021 12 06; 73(11):e4353-e4360.
    View in: PubMed
    Score: 0.031
  71. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA. 2021 11 23; 326(20):2043-2054.
    View in: PubMed
    Score: 0.031
  72. Influenza Vaccine Effectiveness Against Hospitalization in the United States, 2019-2020. J Infect Dis. 2021 09 01; 224(5):813-820.
    View in: PubMed
    Score: 0.031
  73. Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance - Eight U.S. Locations, December 2020-August 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 27; 70(34):1167-1169.
    View in: PubMed
    Score: 0.031
  74. Influenza Vaccine Effectiveness in Inpatient and Outpatient Settings in the United States, 2015-2018. Clin Infect Dis. 2021 08 02; 73(3):386-392.
    View in: PubMed
    Score: 0.030
  75. Effects of Prior Season Vaccination on Current Season Vaccine Effectiveness in the United States Flu Vaccine Effectiveness Network, 2012-2013 Through 2017-2018. Clin Infect Dis. 2021 08 02; 73(3):497-505.
    View in: PubMed
    Score: 0.030
  76. Low Influenza Vaccine Effectiveness Against A(H3N2)-Associated Hospitalizations in 2016-2017 and 2017-2018 of the Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). J Infect Dis. 2021 06 15; 223(12):2062-2071.
    View in: PubMed
    Score: 0.030
  77. Sample size considerations for mid-season estimates from a large influenza vaccine effectiveness network in the United States. Vaccine. 2021 06 08; 39(25):3324-3328.
    View in: PubMed
    Score: 0.030
  78. Differences between Frequentist and Bayesian inference in routine surveillance for influenza vaccine effectiveness: a test-negative case-control study. BMC Public Health. 2021 03 16; 21(1):516.
    View in: PubMed
    Score: 0.030
  79. Influenza vaccination coverage among persons seeking outpatient medical care for acute respiratory illness in five states in the United States, 2011-2012 through 2018-2019. Vaccine. 2021 03 19; 39(12):1788-1796.
    View in: PubMed
    Score: 0.029
  80. Reducing Antibiotic Use in Ambulatory Care Through Influenza Vaccination. Clin Infect Dis. 2020 12 31; 71(11):e726-e734.
    View in: PubMed
    Score: 0.029
  81. Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015-16 to 2018-19. Vaccine. 2020 09 29; 38(42):6562-6569.
    View in: PubMed
    Score: 0.028
  82. Influenza vaccine effectiveness among outpatients in the US Influenza Vaccine Effectiveness Network by study site 2011-2016. Influenza Other Respir Viruses. 2020 07; 14(4):380-390.
    View in: PubMed
    Score: 0.028
  83. Spread of Antigenically Drifted Influenza A(H3N2) Viruses and Vaccine Effectiveness in the United States During the 2018-2019 Season. J Infect Dis. 2020 01 01; 221(1):8-15.
    View in: PubMed
    Score: 0.027
  84. Prevention of Influenza Hospitalization Among Adults in the United States, 2015-2016: Results From the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). J Infect Dis. 2019 09 13; 220(8):1265-1275.
    View in: PubMed
    Score: 0.027
  85. Influenza vaccine effectiveness among patients with high-risk medical conditions in the United States, 2012-2016. Vaccine. 2018 12 18; 36(52):8047-8053.
    View in: PubMed
    Score: 0.025
  86. Influenza vaccine effectiveness in older adults compared with younger adults over five seasons. Vaccine. 2018 02 28; 36(10):1272-1278.
    View in: PubMed
    Score: 0.024
  87. 2015-2016 Vaccine Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children in the United States. Clin Infect Dis. 2018 02 10; 66(5):665-672.
    View in: PubMed
    Score: 0.024
  88. Burden of medically attended influenza infection and cases averted by vaccination - United States, 2013/14 through 2015/16 influenza seasons. Vaccine. 2018 01 25; 36(4):467-472.
    View in: PubMed
    Score: 0.024
  89. Prior-Season Vaccination and Risk of Influenza During the 2014-2015 Season in the United States. J Infect Dis. 2017 07 15; 216(2):284-285.
    View in: PubMed
    Score: 0.023
  90. Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. MMWR Morb Mortal Wkly Rep. 2015 Jan 16; 64(1):10-5.
    View in: PubMed
    Score: 0.019
  91. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age. Pediatr Infect Dis J. 2011 Oct; 30(10):e179-85.
    View in: PubMed
    Score: 0.015
  92. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol. 2003 Aug 15; 158(4):305-11.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.